دورية أكاديمية
A randomized clinical trial assessing theranostic-guided corneal cross-linking for treating keratoconus. The Argo protocol
| العنوان: | A randomized clinical trial assessing theranostic-guided corneal cross-linking for treating keratoconus. The Argo protocol |
|---|---|
| المؤلفون: | Roszkowska, Anna Maria, Lombardo, Giuseppe, Mencucci, Rita, Scorcia, Vincenzo, Giannaccare, Giuseppe, Vestri, Annarita, Alunni Fegatelli, Danilo, Bernava, Giuseppe Massimo, Serrao, Sebastiano, Lombardo, Marco |
| المساهمون: | Roszkowska, Anna Maria, Lombardo, Giuseppe, Mencucci, Rita, Scorcia, Vincenzo, Giannaccare, Giuseppe, Vestri, Annarita, Alunni Fegatelli, Danilo, Bernava, Giuseppe Massimo, Serrao, Sebastiano, Lombardo, Marco |
| بيانات النشر: | SPRINGER VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS |
| سنة النشر: | 2023 |
| المجموعة: | Sapienza Università di Roma: CINECA IRIS |
| مصطلحات موضوعية: | corneal cross-linking, keratoconu, ribofravin, theranostics |
| الوصف: | The Assessment of theranostic guided riboflavin/UV-A corneal cross-linking for treatment of keratoconus (ARGO; registration number NCT05457647) clinical trial tests the hypothesis that theranostic-guided riboflavin/UV-A corneal cross-linking (CXL) can provide predictable clinical efficacy for halting keratoconus progression, regardless of treatment protocol, i.e., either with or without epithelial removal. Theranostics is an emerging therapeutic paradigm of personalized and precision medicine that enables real-time monitoring of image-guided therapy. In this trial, the theranostic software module of a novel UV-A medical device will be validated in order to confirm its accuracy in estimating corneal cross-linking efficacy in real time. During CXL procedure, the theranostic UV-A medical device will provide the operator with an imaging biomarker, i.e., the theranostic score, which is calculated by non-invasive measurement of corneal riboflavin concentration and its UV-A light mediated photo-degradation. ARGO is a randomized multicenter clinical trial in patients aged between 18 and 40 years with progressive keratoconus aiming to validate the theranostic score by assessing the change of the maximum keratometry point value at 1-year postoperatively. A total of 50 participants will be stratified with allocation ratio 1:1 using a computer-generated stratification plan with blocks in two treatment protocols, such as epithelium-off or epithelium-on CXL. Following treatment, participants will be monitored for 12 months. Assessment of safety and performance of theranostic-guided corneal cross-linking treatment modality will be determined objectively by corneal tomography, corneal endothelial microscopy, visual acuity testing and slit-lamp eye examination. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/36587174; info:eu-repo/semantics/altIdentifier/wos/WOS:000906309400001; volume:43; issue:7; firstpage:2315; lastpage:2328; numberofpages:14; journal:INTERNATIONAL OPHTHALMOLOGY; https://hdl.handle.net/11573/1700332Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85145335175 |
| DOI: | 10.1007/s10792-022-02628-4 |
| الإتاحة: | https://doi.org/10.1007/s10792-022-02628-4Test https://hdl.handle.net/11573/1700332Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.18EC7F2E |
| قاعدة البيانات: | BASE |
| DOI: | 10.1007/s10792-022-02628-4 |
|---|